CEMI - Chembio Diagnostics files for emergency use of DPP SARS-CoV-2 Antigen test

Chembio Diagnostics (CEMI) has submitted an application for Emergency Use Authorization ((EUA)) to the FDA for the DPP SARS-CoV-2 Antigen test system to detect COVID-19 antigens in only 20 minutes.The test system consists of a DPP SARS-CoV-2 Antigen test cartridge, a DPP Micro Reader optical analyzer and a minimally-invasive nasal swab. “The DPP platform is ideally suited as a cost-effective system for rapid testing at the point of care and can help expand patient access to testing," said Richard Eberly, President and CEO. See how Raid Antigen test works: Chembio’s portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System, DPP HIV 1/2 Assay, DPP Zika IgM System, and DPP Ebola Antigen System.Additionally, DPP-based tests have received regulatory approvals from the World Health Organization, CE-Mark and other global organizations.A look at Rapid COVID-19 Timeline:Shares up 4% after-hours.

For further details see:

Chembio Diagnostics files for emergency use of DPP SARS-CoV-2 Antigen test